TruSight™ Hereditary Cancer Panel

NGS panel for hereditary cancer studies integrating the analysis of 113 clinically relevant genes with a rapid workflow and high coverage uniformity for the consistent detection of SNVs, indels, and CNVs.

Detailed Description

Operating Principle

An end-to-end solution based on hybrid capture of 113 genes (all exons covered plus ±20 bp regions) and library preparation via bead-linked transposome (eBLT) tagmentation, delivering ready-to-sequence libraries in 6.5 hours. Compatible with Illumina benchtop sequencing systems. Data processing is performed via BaseSpace™ or DRAGEN™, and features compatibility for tertiary analysis in Emedgene.

Library preparation workflow

Clinical Applications

Designed to support genetic counseling units, oncology, and oncogenetics laboratories in enhancing the diagnosis and risk stratification of patients with hereditary cancer predisposition syndromes through a comprehensive assessment of germline variants associated with these pathologies.

Genes included in key clinical guidelines

Benefits

This panel stands out as a reference solution for laboratories seeking efficiency without compromising quality: a fast, streamlined workflow takes you from sample to data in ~48 hours, with only ~2 hours of hands-on time, while excellent coverage uniformity supports the accurate detection of SNVs, indels, and CNVs.

Furthermore, its high flexibility allows easy scaling to meet different laboratory needs, enabling high-throughput clinical routines.

TruSight Hereditary Cancer Panel Table

Intended Audience / User

Laboratories and research groups studying genetic predisposition to cancer that require a multi-gene germline panel with high uniformity and scaling flexibility.

Key Features

Expert-designed coverage: 403 kb total footprint covering 113 genes (all exons ±20 bp) with 10,341 probes for curated, comprehensive content, ready for clinical performance.
Risk stratification capabilities: The panel features 125 integrated SNPs (48 for sample tracking and 77 for polygenic risk score in breast cancer).
Consistent data quality: Comprehensive and uniform coverage across 113 cancer predisposition genes (±20 bp intronic).
Analytical confidence: Reliable detection of SNVs, indels, and CNVs with high uniformity and concordance in validations against reference standards.
Flexible scalability: From 2 to 256 samples per run with an average depth of 300x (minimum 100x).
Full compatibility: Works with automation systems and all Illumina sequencing instruments.
High sample input versatility: From genomic DNA to direct blood or saliva samples using the Flex Lysis Reagent kit.

Area:

Hereditary cancer, Molecular Genetics, Targeted study of specific pathologies

Brand:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

Devyser Thalassemia v2

Devyser Thalassemia v2 is a fast and robust NGS solution designed for the detection of genetic variants in alpha and beta thalassemia. It offers comprehensive coverage of the globin genes HBA1, HBA2, HBB, HBD, HBG1, and HBG2, and includes the detection of single nucleotide variants (SNVs), insertions/deletions (Indels), and copy number variations (CNVs). Additionally, it…
Devyser
Next Generation Sequencing (NGS)

SOPHiA DDM™ Enhanced Clinical Exome Solution

A comprehensive solution combining a capture-based enrichment kit and the SOPHiA DDM™ platform for advanced clinical exome analysis, featuring targeted enhancements to increase coverage in critical regions and detect complex variants in a single workflow. Detailed Description Operating Principle A genomic application integrating a capture enrichment kit with the advanced analytical modules of the SOPHiA…
SOPHIA Genetics
Next Generation Sequencing (NGS)

1928 Platform

Cloud-based bioinformatics platform for the standardized and automated analysis of microbiology sequencing data, complemented by hospital genomic surveillance to detect, track, and prevent infections and antimicrobial resistance (AMR). Rapid cloud genomic analysis with seamless integration into hospital workflows; ISO-certified data management, and support from bioinformatics specialists. Fast, user-friendly, and maintenance-free service. Product Description A solution…
1928 Diagnostics
Next Generation Sequencing (NGS)

CosMx Spatial Molecular Imager (SMI)

Bruker's CosMX™ Spatial Molecular Imager (SMI) is an advanced platform for in situ multi-omic spatial analysis at the single-cell level. CosMx SMI is the only in situ imaging platform that offers single-cell spatial biology of the whole transcriptome with unparalleled accuracy, sensitivity, and genomic breadth. It provides spatial multi-omics on formalin-fixed paraffin-embedded (FFPE) and fresh…
Bruker
Spatial Biology